memantine has been researched along with Dyskinesia, Medication-Induced in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Memantine was well tolerated, without any serious adverse events, or worsening in the parkinsonian motor score." | 2.82 | Memantine and reduced time with dyskinesia in Parkinson's Disease. ( Wictorin, K; Widner, H, 2016) |
| "Memantine treatment was associated with lower axial motor symptom and dyskinesia scores but did not improve gait." | 2.78 | Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. ( Allorge, D; Blum, D; Bordet, R; Defebvre, L; Delval, A; Destée, A; Devos, D; Duhamel, A; Dujardin, K; Hossein-Foucher, C; Moreau, C; Petyt, G; Sablonnière, B; Schraen, S; Tiffreau, V, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wictorin, K | 1 |
| Widner, H | 1 |
| Varanese, S | 1 |
| Howard, J | 1 |
| Di Rocco, A | 1 |
| Moreau, C | 1 |
| Delval, A | 1 |
| Tiffreau, V | 1 |
| Defebvre, L | 1 |
| Dujardin, K | 1 |
| Duhamel, A | 1 |
| Petyt, G | 1 |
| Hossein-Foucher, C | 1 |
| Blum, D | 1 |
| Sablonnière, B | 1 |
| Schraen, S | 1 |
| Allorge, D | 1 |
| Destée, A | 1 |
| Bordet, R | 1 |
| Devos, D | 1 |
| Vidal, EI | 1 |
| Fukushima, FB | 1 |
| Valle, AP | 1 |
| Villas Boas, PJ | 1 |
| Andreassen, OA | 1 |
| Waage, J | 1 |
| Finsen, B | 1 |
| Jørgensen, HA | 1 |
| Wesemann, W | 1 |
| Sontag, KH | 1 |
| Maj, J | 1 |
| Hanağasi, HA | 1 |
| Kaptanoglu, G | 1 |
| Sahin, HA | 1 |
| Emre, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Memantine to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Monocentric Trial[NCT01108029] | Phase 4 | 28 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for memantine and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
[Pharmacodynamics and pharmacokinetics of memantine].
Topics: Amantadine; Animals; Antidepressive Agents; Body Temperature; Catalepsy; Dopamine; Dyskinesia, Drug- | 1983 |
2 trials available for memantine and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Memantine and reduced time with dyskinesia in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Excit | 2016 |
Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Double-Blind Method; Dyskinesi | 2013 |
4 other studies available for memantine and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Le | 2010 |
Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia.
Topics: Aged, 80 and over; Antiparkinson Agents; Dementia; Dopamine Agents; Dyskinesia, Drug-Induced; Humans | 2013 |
Memantine attenuates the increase in striatal preproenkephalin mRNA expression and development of haloperidol-induced persistent oral dyskinesias in rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cell Count; Corpus Striatum; Dopamine Antagonists; | 2003 |
The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.
Topics: Adult; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2000 |